L Pyle

1.1k total citations
18 papers, 810 citations indexed

About

L Pyle is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, L Pyle has authored 18 papers receiving a total of 810 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in L Pyle's work include Renal cell carcinoma treatment (11 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Genomics and Diagnostics (4 papers). L Pyle is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Genomics and Diagnostics (4 papers). L Pyle collaborates with scholars based in United Kingdom, United States and Netherlands. L Pyle's co-authors include Martin Gore, Tim Eisen, Roger A’Hern, Ian Mak, Francisco Sapunar, Matthew Vaughan, Stephen R.D. Johnston, Chris Boshoff, IE Smith and Peter F.A. Mulders and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

L Pyle

18 papers receiving 792 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Pyle United Kingdom 12 441 359 301 235 181 18 810
Fabian Zohren United States 14 331 0.8× 690 1.9× 288 1.0× 230 1.0× 98 0.5× 44 1.1k
Deborah Ricci United States 15 261 0.6× 399 1.1× 474 1.6× 262 1.1× 149 0.8× 51 876
Heidi Steinfeldt United States 8 694 1.6× 401 1.1× 586 1.9× 254 1.1× 63 0.3× 10 1.1k
Yu-Nien Sun United States 10 528 1.2× 332 0.9× 566 1.9× 196 0.8× 61 0.3× 12 1.4k
R. Basser Australia 15 199 0.5× 179 0.5× 397 1.3× 115 0.5× 195 1.1× 31 731
Yu‐Nien Sun United States 13 298 0.7× 129 0.4× 206 0.7× 120 0.5× 80 0.4× 30 702
Paola Aimone Switzerland 17 372 0.8× 338 0.9× 549 1.8× 135 0.6× 235 1.3× 43 1.1k
Joseph M. Gozgit United States 13 580 1.3× 265 0.7× 282 0.9× 151 0.6× 209 1.2× 25 1.1k
Darrel P. Cohen United States 13 288 0.7× 788 2.2× 280 0.9× 160 0.7× 70 0.4× 31 1.2k
Maja J. De Jonge Netherlands 16 471 1.1× 298 0.8× 449 1.5× 114 0.5× 37 0.2× 43 849

Countries citing papers authored by L Pyle

Since Specialization
Citations

This map shows the geographic impact of L Pyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Pyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Pyle more than expected).

Fields of papers citing papers by L Pyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Pyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Pyle. The network helps show where L Pyle may publish in the future.

Co-authorship network of co-authors of L Pyle

This figure shows the co-authorship network connecting the top 25 collaborators of L Pyle. A scholar is included among the top collaborators of L Pyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Pyle. L Pyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Schmidinger, Manuela, Romano Danesi, Robert J. Jones, et al.. (2017). Individualized Dosing with Axitinib: Rationale and Practical Guidance. Future Oncology. 14(9). 861–875. 14 indexed citations
2.
Pyle, L, et al.. (2012). Side effects of pazopanib in renal cell carcinoma. Cancer Nursing Practice. 11(3). 16–22. 1 indexed citations
3.
Eisen, Tim, Cora N. Sternberg, Caroline Robert, et al.. (2012). Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. JNCI Journal of the National Cancer Institute. 104(2). 93–113. 156 indexed citations
4.
5.
Larkin, James, L Pyle, & Martin Gore. (2010). Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies. The Oncologist. 15(11). 1135–1146. 20 indexed citations
6.
Tuthill, Mark, Ravi Barod, L Pyle, et al.. (2009). A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Reports. 2009. bcr0820080732–bcr0820080732. 12 indexed citations
7.
Patel, Poulam M., Peter J. Selby, Barry W. Hancock, et al.. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(6). 898–903. 16 indexed citations
8.
Benepal, T., Ann L. Jackman, L Pyle, et al.. (2005). A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. British Journal of Cancer. 93(8). 868–875. 3 indexed citations
9.
Waters, Justin S., L Pyle, Maggie James, et al.. (2004). Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. British Journal of Cancer. 91(10). 1763–1768. 43 indexed citations
10.
Ahmad, T., Richard Marais, L Pyle, et al.. (2004). BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Journal of Clinical Oncology. 22(14_suppl). 7506–7506. 39 indexed citations
11.
Ahmad, T., Richard Marais, L Pyle, et al.. (2004). BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Journal of Clinical Oncology. 22(14_suppl). 7506–7506. 21 indexed citations
12.
Gibbs, David D., L Pyle, Matthew Vaughan, et al.. (2002). A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. British Journal of Cancer. 86(9). 1379–1384. 29 indexed citations
13.
Stebbing, Justin, Charlotte Benson, Timothy Eisen, et al.. (2001). The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer. 85(7). 953–958. 8 indexed citations
14.
Stebbing, Justin, Charlotte Benson, Tim Eisen, et al.. (2001). The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer. 85(7). 953–958. 89 indexed citations
15.
Eisen, Tim, Chris Boshoff, Ian Mak, et al.. (2000). Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. British Journal of Cancer. 82(4). 812–817. 274 indexed citations
16.
Eisen, Tim, Chris Boshoff, Ian Mak, et al.. (1999). A PHASE II STUDY OF CONTINUOUS LOW DOSE THALIDOMIDE IN PATIENTS WITH RENAL CELL. MELANOMA, OVARIAN AND BREAST CANCER. Journal of Immunotherapy. 22(5). 458–458. 1 indexed citations
17.
Johnson, Steven W., et al.. (1997). A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma. European Journal of Cancer. 33. S120–S120. 9 indexed citations
18.
Pyle, L, et al.. (1967). Functional adrenocortical carcinoma in a dog.. PubMed. 150(7). 760–6. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabian Zohren Breakdown of academic impact, for papers by Deborah Ricci Breakdown of academic impact, for papers by Heidi Steinfeldt Breakdown of academic impact, for papers by Yu-Nien Sun Breakdown of academic impact, for papers by R. Basser Breakdown of academic impact, for papers by Yu‐Nien Sun Breakdown of academic impact, for papers by Paola Aimone Breakdown of academic impact, for papers by Joseph M. Gozgit Breakdown of academic impact, for papers by Darrel P. Cohen Breakdown of academic impact, for papers by Maja J. De Jonge
Rankless by CCL
2026